Derechos de autor 2025 Biociencias (UNAD)
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Efectos adversos de la quimioterapia en pacientes infantes con leucemia linfoblástica aguda
La leucemia linfoblástica aguda (LLA), también conocida como leucemia linfocítica aguda, es la neoplasia maligna más común y debilitante en la infancia, representando aproximadamente el 80% de los casos de leucemia en niños. A pesar de ser una de las leucemias agudas con las tasas de curación más altas, gracias a la intensificación de los protocolos de quimioterapia, sigue generando efectos adversos en los pacientes pediátricos. La quimioterapia, principal tratamiento para esta enfermedad, no solo destruye las células cancerosas, sino que también ralentiza su crecimiento. Sin embargo, su aplicación no está exenta de complicaciones, que en algunos casos superan las propias de la enfermedad. Entre las principales complicaciones que presentan mayor incidencia se encuentran las afecciones neurológicas, musculoesqueléticas, bucodentales y metabólicas, todas ellas asociadas, en su mayoría, a la toxicidad de los medicamentos administrados. Estas complicaciones afectan significativamente el desarrollo físico, psicomotor y la calidad de vida de los niños que padecen esta forma de leucemia hematológica.
(1) Lustosa D, de Almeida F, Cavalcante F, de Oliveira M. Acute lymphoblastic leukemia in children and adolescents: prognostic factors and analysis of survival. Revista Brasileira de Hematologia e Hemoterapia [Internet]. julio de 2015
(2) Lassaletta-Atienza A. Leucemias. Leucemia linfoblástica aguda. Pediatr Integral. 2012;XVI(6):453-462
(3) Young Y, Miller: Incidence or malignant tumours in U.S. children. J. Pediatr 1975;86: 254-58. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714852/
(4) Pui CH, Evans W: Drug Therapy: Acute lymphoblastic leukemia. New Engl J Med 1998; 339:9 605-15. Disponible en: https://pubmed.ncbi.nlm.nih.gov/16407512/
(5) VelentzaL, ZamánF, SavendahlL. Bone health in glucocorticoid-treated childhood acute lymphoblastic leukemia. Crit Rev. Oncol hematol. 2021;168:103492
(6) Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020 Nov 1;105(11):2524-2539. doi: 10.3324/haematol.2020.247031. PMID: 33054110; PMCID: PMC7604619.
(7) Pui CH, Evans WE. Tratamiento de leucemia linfoblástica aguda. N. ingl. J. Med 2006;354(2):166-78. http://doi.org/cggrpn.
(8) Rodríguez MC, Galván DM. Efectos de la quimioterapia en el sistema músculo esquelético de niños y adolescentes con leucemia linfoblástica aguda. Revista Universidad y Salud (2014). Disponible en: https://revistas.udenar.edu.co/index.php/usalud/article/view/2379
(9) Aricò M, Boccalatte MF, Silvestri D, Barisone E, Messina C, Chiesa R, Santoro N, Tamaro P, Lippi A, Gallisai D, Basso G, De Rossi G; Associazione Italiana di Ematologia ed Oncologia Pediatrica. Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica. 2003 Jul;88(7):747-53. PMID: 12857552.
(10) Juárez-López MLA, Solano-Silva MN, Fragoso-Ríos R, et al. Alteraciones bucodentales en niños con leucemia linfoblástica aguda bajo tratamiento con quimioterapia. Rev Med Inst Mex Seguro Soc. 2018;56(2):132-135.
(11) Kuskonmaz B, Unal S, Gumruk F, Cetin M, Tuncer AM, Gurgey A. The neurologic complications in pediatric acute lymphoblastic leukemia patients excluding leukemic infiltration. Leuk Res. 2006 May;30(5):537-41. doi: 10.1016/j.leukres.2005.09.009. Epub 2005 Oct 24. PMID: 16249027.
(12) Palma R, Paula, Folatre B, Isabel, Kyonen L, Mónica, Cea S, Gustavo, Yilorm B, Mania, & Martínez D, Pilar. (2013). Hiperglicemia en niños con leucemia linfoblástica aguda en tratamiento con L-asparaginasa. Revista chilena de pediatría, 84(4), 387-395. https://dx.doi.org/10.4067/S0370-41062013000400004
(13) Baytan B, Evim MS, Güler S, Güneş AM, Okan M. Acute Central Nervous System Complications in Pediatric Acute Lymphoblastic Leukemia. Pediatr Neurol. 2015 Oct;53(4):312-8. doi: 10.1016/j.pediatrneurol.2015.03.006. Epub 2015 May 15. PMID: 26202590.
(14) Rahiman EA, Rajendran A, Sankhyan N, Singh P, Muralidharan J, Bansal D, Trehan A. Acute neurological complications during acute lymphoblastic leukemia therapy: A single-center experience over 10 years. Indian J Cancer. 2021 Oct-Dec;58(4):545-552. doi: 10.4103/ijc.IJC_422_19. PMID: 34380827.
(15) Parasole R, Petruzziello F, Menna G, Mangione A, Cianciulli E, Buffardi S, Marchese L, Nastro A, Misuraca A, Poggi V. Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution. Leuk Lymphoma. 2010 Jun;51(6):1063-71. doi: 10.3109/10428191003754608. PMID: 20470218.
(16) Kembhavi SA, Somvanshi S, Banavali S, Kurkure P, Arora B. Pictorial essay: Acute neurological complications in children with acute lymphoblastic leukemia. Indian J Radiol Imaging. 2012 Apr;22(2):98-105. doi: 10.4103/0971-3026.101080. PMID: 23162250; PMCID: PMC3498649.
(17) Millan NC, Pastrana A, Guitter MR, Zubizarreta PA, Monges MS, Felice MS. Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia. Leuk Res. 2018 Feb;65:86-93. doi: 10.1016/j.leukres.2017.12.010. Epub 2018 Jan 2. PMID: 29328996.
(18) Intusoma U, Nakorn CN, Chotsampancharoen T. Intracranial Hemorrhage in Childhood Acute Leukemia: Incidence, Characteristics, and Contributing Factors. Pediatr Neurol. 2019 Oct;99:23-30. doi: 10.1016/j.pediatrneurol.2019.06.005. Epub 2019 Jun 13. PMID: 31326259.
(19) Pardes-Chavanes P, Afanetti M, Boyer C, Poirée M. Hémorragie cérébrale fatale en cours d’induction d’une leucémie aiguë lymphoblastique [Fatal central nervous system hemorrhage during acute lymphoblastic leukemia induction]. Arch Pediatr. 2016 Dec;23(12):1260-1263. French. doi: 10.1016/j.arcped.2016.08.014. Epub 2016 Oct 12. PMID: 27743763.
(20) Alqasim AMZ, Al-Hadithi RH, Al-Khalidi AN. Coagulopathic side effect of L-asparaginase on fibrinogen level in childhood acute lymphoblastic leukemia during induction phase. Hematol Oncol Stem Cell Ther. 2019 Mar;12(1):67-69. doi: 10.1016/j.hemonc.2018.01.003. Epub 2018 Feb 1. PMID: 29406239.
(21) Kieslich M, Porto L, Lanfermann H, Jacobi G, Schwabe D, Böhles H. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2003 Jun;25(6):484-7. doi: 10.1097/00043426-200306000-00011. PMID: 12794528.
(22) Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006; 108: 2216–2222.
(23) Kamali K, Taghavinasab R, Haghpanah S, Bordbar MR, Kamalipour P. Brain MRI Findings in Children with Acute Lymphoblastic Leukemia. IJBC 2017; 9(2): 37-43.
(24) Beinart G, Damon L. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol. 2004 Dec;77(4):331-5. doi: 10.1002/ajh.20230. PMID: 15551293.
(25) Reddick WE, Glass JO, Helton KJ, Langston JW, Xiong X, Wu S, Pui CH. Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR Am J Neuroradiol. 2005 May;26(5):1263-9. PMID: 15891195; PMCID: PMC2396789.
(26) Rijmenams I, Moechars D, Uyttebroeck A, Radwan A, Blommaert J, Deprez S, Sunaert S, Segers H, Gillebert CR, Lemiere J, Sleurs C. Age- and Intravenous Methotrexate-Associated Leukoencephalopathy and Its Neurological Impact in Pediatric Patients with Lymphoblastic Leukemia. Cancers (Basel). 2021 Apr 16;13(8):1939. doi: 10.3390/cancers13081939. PMID: 33923795; PMCID: PMC8073318.
(27) Barbosa CM, Nakamura C, Terreri MT, Lee ML, Petrilli AS, Hilário MO. Manifestações músculo-esqueléticas como apresentação inicial das leucemias agudas na infância [Musculoskeletal manifestations as the onset of acute leukemias in childhood]. J Pediatr (Rio J). 2002 Nov-Dec;78(6):481-4. Portuguese. PMID: 14647728.
(28) Pécheux L, Forget P, Geurten C, Rausin L, Nicolescu R, Hoyoux C. ‘09[Bone disorders and complications of pediatric acute lymphoblastic leukemia : monocentric study and review of the literature]. Rev Med Liege. 2018 Nov;73(11):575-582. French. PMID: 30431247.
(29) te Winkel ML, Pieters R, Hop WC, Roos JC, Bökkerink JP, Leeuw JA, Bruin MC, Kollen WJ, Veerman AJ, de Groot-Kruseman HA, van der Sluis IM, van den Heuvel-Eibrink MM. Bone mineral density at diagnosis determines fracture rate in children with acute lymphoblastic leukemia treated according to the DCOG-ALL9 protocol. Bone. 2014 Feb;59:223-8. doi: 10.1016/j.bone.2013.11.017. Epub 2013 Nov 25. PMID: 24287213.
(30) Alos N, Grant RM, Ramsay T, Halton J, Cummings EA, Miettunen PM, Abish S, Atkinson S, Barr R, Cabral DA, Cairney E, Couch R, Dix DB, Fernandez CV, Hay J, Israels S, Laverdière C, Lentle B, Lewis V, Matzinger M, Rodd C, Shenouda N, Stein R, Stephure D, Taback S, Wilson B, Williams K, Rauch F, Siminoski K, Ward LM. High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy. J Clin Oncol. 2012 Aug 1;30(22):2760-7. doi: 10.1200/JCO.2011.40.4830. Epub 2012 Jun 25. PMID: 22734031; PMCID: PMC4022591.
(31) Strauss AJ, Su JT, Dalton VM, Gelber RD, Sallan SE, Silverman LB. Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol. 2001 Jun 15;19(12):3066-72. doi: 10.1200/JCO.2001.19.12.3066. PMID: 11408503.
(32) Ward LM, Ma J, Lang B, Ho J, Alos N, Matzinger MA, Shenouda N, Lentle B, Jaremko JL, Wilson B, Stephure D, Stein R, Sbrocchi AM, Rodd C, Lewis V, Israels S, Grant RM, Fernandez CV, Dix DB, Cummings EA, Couch R, Cairney E, Barr R, Abish S, Atkinson SA, Hay J, Rauch F, Moher D, Siminoski K, Halton J; Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium. Bone Morbidity and Recovery in Children With Acute Lymphoblastic Leukemia: Results of a Six-Year Prospective Cohort Study. J Bone Miner Res. 2018 Aug;33(8):1435-1443. doi: 10.1002/jbmr.3447. Epub 2018 May 22. PMID: 29786884.
(33) Arikoski P, Komulainen J, Riikonen P, Jurvelin JS, Voutilainen R, Kröger H. Reduced bone density at completion of chemotherapy for a malignancy. Arch Dis Child. 1999 Feb;80(2):143-8. doi: 10.1136/adc.80.2.143. PMID: 10325729; PMCID: PMC1717834.
(34) Fischer G Sylvia, Neira L Laura, Ferreiro M Myriam, Torres C María Teresa, Giadrosich R Vinka, Milinarsky T Aída et al . Densitometría ósea en niños leucémicos al completar el primer mes de quimioterapia. Rev. méd. Chile [Internet]. 2005 Ene; 133( 1 ): 71-76. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005000100009&lng=es. http://dx.doi.org/10.4067/S0034-98872005000100009.
(35) Inaba H, Cao X, Han AQ, Panetta JC, Ness KK, Metzger ML, Rubnitz JE, Ribeiro RC, Sandlund JT, Jeha S, Cheng C, Pui CH, Relling MV, Kaste SC. Bone mineral density in children with acute lymphoblastic leukemia. Cancer. 2018 Mar 1;124(5):1025-1035. doi: 10.1002/cncr.31184. Epub 2017 Dec 19. PMID: 29266176; PMCID: PMC5821586.
(36) Van der Sluis IM, van den Heuvel-Eibrink MM, Hählen K, Krenning EP, de Muinck Keizer-Schrama SM. Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia. J Pediatr. 2002 Aug;141(2):204-10. doi: 10.1067/mpd.2002.125728. PMID: 12183715.
(37) Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, Neale G, Howard SC, Evans WE, Pui CH, Relling MV. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2011 Feb 24;117(8):2340-7; quiz 2556. doi: 10.1182/blood-2010-10-311969. Epub 2010 Dec 10. PMID: 21148812; PMCID: PMC3062406.
(38) Ali N, Gohar S, Zaky I, Elghoneimy A, Youssef S, Sameer G, Yassin D, Salem S, Magdi H, Sidhom I. Osteonecrosis in children with acute lymphoblastic leukemia: A report from Children's Cancer Hospital Egypt (CCHE). Pediatr Blood Cancer. 2019 Jan;66(1):e27440. doi: 10.1002/pbc.27440. Epub 2018 Sep 5. PMID: 30183135.
(39) Mattano LA , Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol. 2000;18:3262–3272.
(40) te Winkel ML, Pieters R, Hop WC, de Groot-Kruseman HA, Lequin MH, van der Sluis IM, Bökkerink JP, Leeuw JA, Bruin MC, Egeler RM, Veerman AJ, van den Heuvel-Eibrink MM. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2011 Nov 1;29(31):4143-50. doi: 10.1200/JCO.2011.37.3217. Epub 2011 Sep 26. PMID: 21947829.
(41) Castilhos de Oliveira M, Silvana Borges T, Quevedo Miguens SA, Thomazi Gassen H, Camargo Fontanella VR. Oral manifestations in pediatric patients receiving chemotherapy for leukemia. Stomatos [Internet]. 2016 ;22(43):20–30. Disponible en: http://revodonto.bvsalud.org/scielo.php?script=sci_arttext&pid=S1519-44422016000200004
(42) Ponce-Torres E, Ruíz-Rodríguez Mdel S, Alejo-González F, Hernández-Sierra JF, Pozos-Guillén Ade J. Oral manifestations in pediatric patients receiving chemotherapy for acute lymphoblastic leukemia. J Clin Pediatr Dent. 2010 Spring;34(3):275-9. doi: 10.17796/jcpd.34.3.y060151580h301t7. PMID: 20578668.
(43) Azher U, Shiggaon N. Oral health status of children with acute lymphoblastic leukemia undergoing chemotherapy. Indian J Dent Res. 2013 Jul-Aug;24(4):523. doi: 10.4103/0970-9290.118371. PMID: 24047855.
(44) Pereira Pinto L, de Souza LB, Gordón-Núñez MA, Soares RC, de Brito Costa EM, de Aquino AR, Fernandes MZ. Prevention of oral lesions in children with acute lymphoblastic leukemia. Int J Pediatr Otorhinolaryngol. 2006 Nov;70(11):1847-51. doi: 10.1016/j.ijporl.2006.04.016. Epub 2006 Aug 17. PMID: 16914211.
(45) Parra JJ, Alvarado MC, Monsalve P, Costa ALF, Montesinos GA, Parra PA. Oral health in children with acute lymphoblastic leukaemia: before and after chemotherapy treatment. Eur Arch Paediatr Dent. 2020 Feb;21(1):129-136. doi: 10.1007/s40368-019-00454-4. Epub 2019 Jun 18. PMID: 31214964.
(46) Garrocho-Rangel JA, Herrera-Moncada M, Márquez-Preciado R, Tejeda-Nava F, Ortiz-Zamudio JJ, Pozos-Guillén A. Oral mucositis in paediatric acute lymphoblastic leukemia patients receiving methotrexate-based chemotherapy: case series. Eur J Paediatr Dent. 2018 Sep;19(3):239-242. doi: 10.23804/ejpd.2018.19.03.13. PMID: 30063158.
(47) Girish Babu K, Mathew J, Doddamani G, Narasimhaiah J, Naik LK. Oral health of children with acute lymphoblastic leukemia: A review. J Orofac Sci [Internet]. 2016 ;8(1):3.Disponible en: https://www.jofs.in/article.asp?issn=0975-8844;year=2016;volume=8;issue=1;spage=3;epage=11;aulast=Girish
(48) Lowas SR, Marks D, Malempati S. Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009 Jul;52(7):814-8. doi: 10.1002/pbc.21980. PMID: 19260096.
(49) Sonabend RY, McKay SV, Okcu MF, Yan J, Haymond MW, Margolin JF. Hyperglycemia during induction therapy is associated with increased infectious complications in childhood acute lymphocytic leukemia. Pediatr Blood Cancer. 2008 Sep;51(3):387-92. doi: 10.1002/pbc.21624. PMID: 18523991.
(50) Baillargeon J, Langevin AM, Mullins J, Ferry RJ Jr, DeAngulo G, Thomas PJ, Estrada J, Pitney A, Pollock BH. Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2005 Dec;45(7):960-3. doi: 10.1002/pbc.20320. PMID: 15700246; PMCID: PMC3102306.
(51) Cohen-Rosenstock Stephanie, Valverde-Muñoz Kathia. Pancreatitis aguda como efecto adverso de L-asparginasa en el tratamiento de la leucemia linfocítica aguda. Acta méd. costarric [Internet]. 2018 June; 60( 2 ): 30-33. Available from: http://www.scielo.sa.cr/scielo.php?script=sci_arttext&pid=S0001-60022018000200030&lng=en.
(52) Treepongkaruna S, Thongpak N, Pakakasama S, Pienvichit P, Sirachainan N, Hongeng S. Acute pancreatitis in children with acute lymphoblastic leukemia after chemotherapy. J Pediatr Hematol Oncol. 2009 Nov;31(11):812-5. doi: 10.1097/MPH.0b013e3181b87035. PMID: 19801
(53) Flores-Calderón J, Exiga-Gonzaléz E, Morán-Villota S, Martín-Trejo J, Yamamoto-Nagano A. Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase. J Pediatr Hematol Oncol. 2009 Oct;31(10):790-3. doi: 10.1097/MPH.0b013e3181b794e8. PMID: 19770681.
(54) Wolthers BO, Frandsen TL, Baruchel A, Attarbaschi A, Barzilai S, Colombini A, et al. Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. Lancet Oncol. 2017 Sep;18:1238-1248948.
(55) Ballón Cossío David. L-Asparaginasa, un arma de doble filo pero de vital importancia. Rev. bol. ped. [Internet]. 2014; 53( 1 ): 24-28. Disponible en: http://www.scielo.org.bo/scielo.php?script=sci_arttext&pid=S1024-06752014000100007&lng=es.
(56) Cohen-Rosenstock Stephanie, Valverde-Muñoz Kathia. Pancreatitis aguda como efecto adverso de L-asparginasa en el tratamiento de la leucemia linfocítica aguda. Acta méd. costarric [Internet]. 2018 June; 60( 2 ): 30-33. Available from: http://www.scielo.sa.cr/scielo.php?script=sci_arttext&pid=S0001-60022018000200030&lng=en.
Derechos de autor 2025 Biociencias (UNAD)
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
